Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Leads to Greater Anti-tumor Activity of Docetaxel in Advanced Prostate Cancer

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Lin, Jianzhong ^a   Wu, Hongfei ^a   Shi, Hui ^b   Pan, Wei ^c   Yu, Hongbo ^a   Zhu, Jiageng ^d  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Institute of Planned Parenthood Research   (China)

^c Nanjing Second Hospital   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER TISSUE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CELL PROLIFERATION; CYCLOOXYGENASE 2; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; NF-KAPPA B; NITROBENZENES; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885403153     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076169     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66. doi:10.3322/canjclin.57.1.43. PubMed: 17237035.
2. Mimeault M, Batra SK, (2006) Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27: 1-22. PubMed: 16195239.
3. Clarke NW, (2006) Management of the spectrum of hormone refractory prostate cancer. Eur Urol 50: 428-438. doi:10.1016/j.eururo.2006.05.017. PubMed: 16797118.
4. Albertsen PC, Hanley JA, Fine J, (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293: 2095-2101. doi:10.1001/jama.293.17.2095. PubMed: 15870412.
5. Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, et al. (2007) Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 167:: 5117-5125.
6. Cho KS, Lee JS, Cho NH, Park K, Ham WS, et al. (2008) Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer. Prostate 68: 803-808. doi:10.1002/pros.20743. PubMed: 18302229.
7. Salzberg M, Rochlitz C, Morant R, Thalmann G, Pedrazzini A, et al. (2007) An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie 30: 355-360. doi:10.1159/000102452. PubMed: 17596743.
8. Stavridi F, Karapanagiotou EM, Syrigos KN, (2010) Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev 36: 122-130. doi:10.1016/j.ctrv.2009.06.001. PubMed: 20106600.
9. Pan Y, Zhang JS, Gazi MH, Young CY, (2003) Thecyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun inprostatecancer cells. Cancer Epidemiol Biomarkers Prev 12: 769-774. PubMed: 12917209.
10. Traish AM, Morgentaler A, (2009) Epidermal growth factor receptor expression escapes androgen regulation in prostatecancer: a potential molecular switch for tumour growth. Br J Cancer 101: 1949-1956. doi:10.1038/sj.bjc.6605376. PubMed: 19888222.
11. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, et al. (2004) Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279: 7119-7130. PubMed: 14662770.
12. Borghese C, Cattaruzza L, Pivetta E, Normanno N, De Luca A, et al. (2013) Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. J Cell Biochem.J Cell Biochem 114: 1135-1144. PubMed: 23192362.
13. Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, et al. (2012) Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 18: 6049-6057. doi:10.1158/1078-0432.CCR-12-2219. PubMed: 22977195.
14. Stock D, Groome PA, Siemens DR, (2008) Inflammation and prostate cancer: a future target for prevention and therapy? Urol Clin North Am 35: 117-130. doi:10.1016/j.ucl.2007.09.006. PubMed: 18061030.
15. Fürstenberger G, Krieg P, Müller-Decker K, Habenicht AJ, (2006) What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer 119: 2247-2254. doi:10.1002/ijc.22153. PubMed: 16921484.
16. Cohen BL, Gomez P, Omori Y, Duncan RC, Civantos F, et al. (2006) Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 119: 1082-1087. doi:10.1002/ijc.21749. PubMed: 16557596.
17. Abedinpour P, Baron VT, Welsh J, Borgström P, (2011) Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo. Prostate 71: 813-823. doi:10.1002/pros.21297. PubMed: 21456064.
18. Walter B, Rogenhofer S, Vogelhuber M, Berand A, Wieland WF, Andreesen R, et al. (2010) Modular therapy approach in metastatic castration-refractory prostate cancer. World J Urol 28: 745-750.
19. Dandekar DS, Lokeshwar BL, (2004) Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin Cancer Res 10: 8037-8047. doi:10.1158/1078-0432.CCR-04-1208. PubMed: 15585639.
20. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL, (2005) Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and-9 in prostate cancer cells. Int J Cancer 115: 484-492. doi:10.1002/ijc.20878. PubMed: 15688368.
21. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55. doi:10.1016/0065-2571(84)90007-4. PubMed: 6382953.
22. O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, et al. (2011) Characterisation and manipulation ofdocetaxelresistantprostatecancer cell lines. Mol Cancer 10: 126-139. doi:10.1158/1535-7163.TARG-11-C126. PubMed: 21982118.
23. Galsky MD, Vogelzang NJ, (2010) Docetaxel-based combinationtherapyfor castration- resistantprostatecancer. Ann Oncol 21: 2135-2144.
24. Reuter CW, Morgan MA, Ivanyi P, Fenner M, Ganser A, Grünwald V, (2010) Carboplatin plus weeklydocetaxelas salvagechemotherapyindocetaxel- resistant and castration-resistant prostate cancer. World J Urol 28: 391-398. doi:10.1007/s00345-010-0527-5. PubMed: 20229232.
25. Mimeault M, Johansson SL, Vankatraman G, Moore E, Henichart JP, et al. (2007) Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects ofdocetaxelon metastatic prostate cancercells. Mol Cancer Ther 6: 967-978. doi:10.1158/1535-7163.MCT-06-0648. PubMed: 17363490.
26. Kang JH, Song KH, Jeong KC, Kim S, Choi C, et al. (2011) Involvement ofCox-2in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer 11: 334-337.
27. Park SY, Kim YM, Pyo H, (2010) Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated. Mol Cancer. 9: 222-234. doi:10.1186/1476-4598-9-222. PubMed: 20731837.
28. Farnebo L, Jerhammar F, Ceder R, Grafström RC, Vainikka L, et al. (2011) Combining factors on protein and gene level to predict radioresponse in head and neck cancer cell lines. J Oral Pathol 40: 739-746. doi:10.1111/j.1600-0714.2011.01036.x. PubMed: 21481002.
29. Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, et al. (2011) Dual blockade of theEGFRandCOX-2pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Am J Clin Oncol 34: 581-586. doi:10.1097/COC.0b013e3181fe46a1. PubMed: 21217396.
30. Ali S, Banerjee S, Schaffert JM, El-Rayes BF, Philip PA, et al. (2010) Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. J Cell Biochem 110: 171-181. PubMed: 20213764.
31. Stoppoloni D, Canino C, Cardillo I, Verdina A, Baldi A, et al. (2010) Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer;9: 27. doi:10.1186/1476-4598-9-27. PubMed: 20122271.
32. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, et al. (2005) Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 11: 6261-2699. doi:10.1158/1078-0432.CCR-04-2102. PubMed: 16144930.
33. Lanza-Jacoby S, Burd R, Rosato FE Jr, McGuire K, Little J, et al. (2006) Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer. Clin Cancer Res12: 6161-6169. doi:10.1158/1078-0432.CCR-06-0042. PubMed: 17062693.
34. Codony-Servat J, Marín-Aguilera M, Visa L, García-Albéniz X, Pineda E, et al. (2013) Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. Prostate 73: 512-521. doi:10.1002/pros.22591. PubMed: 23038213.
35. Kim SM, Lee SY, Cho JS, Son SM, Choi SS, et al. (2010) Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB. Eur J Pharmacol 10;631:: 1-9. PubMed: 20056115.
36. Ni, Feng, Gong Yi, Li Linglin, Abdolmaleky HMet al. (2012) Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in mice. PLOS ONE 7: e38802-38811. PubMed: 22693649.
37. Bao, Bin, Ahmad Aamir, Kong Dejuan, Shadan Ali ASet al. (2012) Hypoxia Induced Aggressiveness of Prostate Cancer Cells Is Linked with Deregulated Expression of VEGF, IL-6 and miRNAs That Are Attenuated by CDF. PLOS ONE 7: 43726-43727. doi:10.1371/journal.pone.0043726. PubMed: 22952749.
38. Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, et al. (2011) A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 117: 526-533.
39. Ortholan C, Durivault J, Hannoun-Levi JM, Guyot M, Bourcier C, et al. (2010) Bevacizumab (a VEGF-targeted humanised monoclonal antibody)/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. Eur J Cancer.;46(16):: 3022-3036. doi:10.1016/j.ejca.2010.07.021. PubMed: 20729074.
40. Mathew P, Wen S, Morita S, Thall PF, (2011) Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases.J Interferon Cytokine Res31: 539-544. doi:10.1089/jir.2010.0142. PubMed: 21323568.
41. Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, et al. (2006) Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 66: 4816-4825. doi:10.1158/0008-5472.CAN-05-3752. PubMed: 16651437.